Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Somatic Mutations in Epigenetic Modifiers Identified Using Next Generation Sequencing (NGS) in Diagnostic Samples of CML-CP Can Predict Poor Outcome on Imatinib Which Is Abrogated By Frontline 2G-TKI Therapy

Georgios Nteliopoulos, MSc, PhD, Alexandra Bazeos, MB, BS, MRCP, Gareth Gerrard, PhD, Simone Claudiani, MD, Ed Curry, PhD, Mary Alikian, MSc, PhD, Hui En Foong, Letizia Foroni, MD PhD FRCPath, Jane F. Apperley, MD

Blood (2016) 128 (22): 1223.

https://doi.org/10.1182/blood.V128.22.1223.1223

Published: 2016

Journal Articles

Assessment of Molecular Response in CML Patients with Atypical BCR-ABL Tanscripts. Recommendations By the EUTOS Collaboration

Thomas Ernst, MD, Vivien Schäfer, Helen E White, PhD, Susanne Saussele, MD, Thoralf Lange, MD, Gareth Gerrard, PhD, Nicholas CP Cross, PhD, Andreas Hochhaus, MD

Blood (2016) 128 (22): 1918.

https://doi.org/10.1182/blood.V128.22.1918.1918

Published: 2016

Journal Articles

NGS-Assisted DNA-Based Digital qPCR Facilitates Stratification Of CML Patients In Long-Term Molecular Remission Based On The Presence Of Detectable BCR-ABL1 DNA

Mary Alikian, Peter Ellery, Matrin Forbes, Gareth Gerrard, PhD, Tim Aitman, Dalia Kasperaviciute, Dragana Milojkovic, PhD, David Marin, MD, John M Goldman, MD, Jane F Apperley, MD, Letizia Foroni, MD, Alistair Reid, PhD

Blood (2013) 122 (21): 4006.

https://doi.org/10.1182/blood.V122.21.4006.4006

Published: 2013

Journal Articles

Targeted High-Throughput Sequencing For The Detection Of Mutations Associated With Myeloproliferative Neoplasms

Ferrari Robin, BSc, Sakuntala Ale, Aysha Patel, BSc, Mikel Valgañón, PhD, Hui En Foong, MSc, Mary Alikian, Kikkeri Naresh, Dragana Milojkovic, PhD, Jane F Apperley, MD, Letizia Foroni, MD, Gareth Gerrard, PhD

Blood (2013) 122 (21): 1613.

https://doi.org/10.1182/blood.V122.21.1613.1613

Published: 2013

Journal Articles

The Depth Of ‘Complete’ Molecular Response Predicts Molecular Relapse In Chronic Myeloid Leukaemia Patients On Tyrosine Kinase Inhibitor Therapy

Heledd Thomas, BSc, Jane F Apperley, MD, Richard M Szydlo, PhD, Gareth Gerrard, PhD, David Marin, MD, Dragana Milojkovic, PhD, Letizia Foroni, MD

Blood (2013) 122 (21): 5201.

https://doi.org/10.1182/blood.V122.21.5201.5201

Published: 2013

Journal Articles

Dose Interruption/Reduction Of Tyrosine Kinase Inhibitors In The First 3 Months Of Treatment of CML Is Associated With Inferior Early Molecular Responses and Predicts For An Increased Likelihood Of Discontinuation Of The 1st Line Agent

Jane F Apperley, MD, Richard M Szydlo, PhD, Gareth Gerrard, PhD, James R McCue, Jamie Wardle, Richard E Clark, MD, Stephen G O'Brien, Letizia Foroni, MD

Blood (2013) 122 (21): 93.

https://doi.org/10.1182/blood.V122.21.93.93

Published: 2013

Journal Articles

A Novel Splice Site Variant of hOCT-1 and Response to Imatinib.

Jacob Grinfeld, Juan M Alonso-Dominguez, Mary Alikian, Mikel Valgañón, PhD, Georgios Nteliopoulos, PhD, Deborah L. White, PhD, FFSc(RCPA), David Marin, Corinne Hedgley, Stephen O'Brien, Richard E. Clark, MD, Richard M Szydlo, Jane Apperley, John M Goldman, MD, Letizia Foroni, Gareth Gerrard, PhD

Blood (2012) 120 (21): 2555.

https://doi.org/10.1182/blood.V120.21.2555.2555

Published: 2012

Journal Articles

Can Targeted Therapy for CML Still Learn From Transplant? Using Post-transplant RQ-PCR monitoring to Clarify the Importance of the Depth of Molecular Remission On the Risk of Subsequent Relapse.

Frederick Pimm, Richard Szydlo, PhD, Letizia Foroni, Francesco Dazzi, MD, Jaspal S Kaeda, PhD, Gareth Gerrard, PhD, Alistair Reid, PhD, Mikel Valganon, BSc, Edward J Kanfer, John M Goldman, MD, Dragana Milojkovic, David Marin, Jane Apperley

Blood (2012) 120 (21): 2789.

https://doi.org/10.1182/blood.V120.21.2789.2789

Published: 2012

Journal Articles

Can the Combination of the Measurement of BCR-ABL1 Transcript Levels At 3 and 6 Months Improve the Prognostic Value of the 3 Month Measurement?

Pratap Neelakantan, MRCP, Gareth Gerrard, PhD, Letizia Foroni, Dragana Milojkovic, Jane Apperley, Richard Szydlo, PhD, Marco Bua, Alistair G Reid, BSc, PhD, Katy Rezvani, MBBS, PhD, MRCP, FRCPath, John M Goldman, MD, David Marin

Blood (2012) 120 (21): 68.

https://doi.org/10.1182/blood.V120.21.68.68

Published: 2012

Journal Articles

Is Major Molecular Response a Safe Haven Against Blast Crisis in Cml Patients Treated with Imatinib?

Pratap Neelakantan, MRCP, Dragana Milojkovic, Gareth Gerrard, PhD, Letizia Foroni, Jane Apperley, Richard M Szydlo, Alistair Reid, PhD, Marco Bua, Katy Rezvani, MBBS, PhD, MRCP, FRCPath, John M Goldman, MD, David Marin

Blood (2012) 120 (21): 3760.

https://doi.org/10.1182/blood.V120.21.3760.3760

Published: 2012

Journal Articles

PTCH1 Expression At Diagnosis Reliably Predicts Treatment Failure in Imatinib-Treated Chronic Myeloid Leukaemia Patients

Juan M. Alonso-Dominguez, Sr., MD, Jacob Grinfeld, MD, Mary Alikian, David Marin, Alistair Reid, PhD, Mustafa Daghistani, Jane Apperley, John M Goldman, MD, Corinne Hedgley, Steve O‘Brien, Richard E. Clark, MD, Letizia Foroni, Gareth Gerrard, PhD

Blood (2012) 120 (21): 875.

https://doi.org/10.1182/blood.V120.21.875.875

Published: 2012

Journal Articles

Target Enrichment and High-Throughput Sequencing of 80 Ribosomal Protein Genes to Identify Mutations Associated with Diamond-Blackfan Anaemia.

Gareth Gerrard, PhD, Mikel Valgañón, PhD, Hui En Foong, MSc, Dalia Kasperaviciute, PhD, Michael Müller, PhD, Laurence Game, PhD, Deena Iskander, MRCP, Irene Roberts, Letizia Foroni, MD, PhD, FRCPath, Josu de la Fuente, PhD, FRCP, MRCPCH, FRCPath, Anastasios Karadimitris, MD, PhD

Blood (2012) 120 (21): 2369.

https://doi.org/10.1182/blood.V120.21.2369.2369

Published: 2012

Journal Articles

Prolonged Survival Following Imatinib Failure for CML Patients in CP May Require Multiple TKI Strategies for Responding Patients,

Dragana Milojkovic, MD, Jane F Apperley, MBChB, MD, FRCP, FRCPath, Amr R Ibrahim, Marco Bua, MD, Alistair Reid, PhD, Gareth Gerrard, PhD, Letizia Foroni, MD PhD, Katy Rezvani, MBBS, PhD, MRCP, FRCPath, John M Goldman, David Marin

Blood (2011) 118 (21): 3777.

https://doi.org/10.1182/blood.V118.21.3777.3777

Published: 2011

Journal Articles

The Natural History of RTQ-PCR Levels After the Achievement of Complete Molecular Remission (CMR): Implications for ‘Stopping' Studies

Dragana Milojkovic, MD, Gareth Gerrard, PhD, Christos Paliompeis, Marco Bua, MD, Alistair Reid, PhD, Mary Alikian, Jamshid Khorashad, MD, PhD, John M Goldman, David Marin, Letizia Foroni, MD PhD, Jane F Apperley, MBChB, MD, FRCP, FRCPath

Blood (2011) 118 (21): 605.

https://doi.org/10.1182/blood.V118.21.605.605

Published: 2011

Journal Articles

Assessment of BCR-ABL1 Transcript Levels At 3 Months Is the Only Requirement for Predicting Outcome for Patients with Chronic Myeloid Leukemia Treated with Imatinib

Dragana Milojkovic, MD, Amr R Ibrahim, Letizia Foroni, MD PhD, Claire Lucas, Gareth Gerrard, PhD, Lihui Wang, Richard M Szydlo, Richard E Clark, Jane F Apperley, MBChB, MD, FRCP, FRCPath, Marco Bua, MD, Jiri Pavlu, Christos Paliompeis, Alistair Reid, PhD, Katy Rezvani, MBBS, PhD, MRCP, FRCPath, John M Goldman, David Marin

Blood (2011) 118 (21): 1680.

https://doi.org/10.1182/blood.V118.21.1680.1680

Published: 2011

Journal Articles

Stability of Conversion Factors for BCR-ABL Monitoring -– Implications for the Frequency of Validation Rounds

Martin C. Müller, MD, Umang Munjal, PhD, Philipp Erben, MD, Thomas Lion, MD, PhD, Gerlinde Mitterbauer-Hohendanner, MD, Hakim El Housni, MD, Nancy Boeckx, Renata Zadro, MD, PhD, Jiri Mayer, MD, PhD, Peter Rohon, MD, Jana Rulcova, PhD, Lykke Grubach, Kadri Raudsepp, MD, Veli Kairisto, MD, PhD, Francois-Xavier Mahon, MD, PhD, Claude Preudhomme, MD, Sandrine Hayette, MD, Jean Gabert, MD, Jean-Michel Cayuela, MD, PhD, Christian Thiede, Lars Galonska, MD, Heike Pfeifer, MD, Carsten Hirt, MD, Philippe Schafhausen, MD, Nils von Neuhoff, PhD, Martin Roskos, MD, Christiane Pott, MD, Thoralf Lange, MD, Georg Hess, MD, Susanne Schnittger, PhD, Annika Dufour, MD, Steffen Koschmieder, MD, Frank Stegelmann, MD, Katerina Zoi, MD, PhD, Kostas Stamatopoulos, Hajnalka Andrikovics, MD, PhD, Tali Tohami, MD, PhD, Giovanni Martinelli, MD, Barbara Izzo, PhD, Enrico Gottardi, MD, Mindaugas Stoskus, Dag Andre Nymoen, MD, Tomasz Sacha, MD, Joana Diamond, MD, PhD, Rodica Talmaci, PhD, Andrey Misyurin, MD, Michael V. Dubina, MD, Tadej Pajic, MD, PhD, Josep F. Nomdedeu, MD, Dolors Colomer, MD, PhD, Gisela Barbany-Bustinza, MD, Hans Ehrencrona, MD, Elisabeth Oppliger Leibundgut, PhD, Jeroen Janssen, MD, Vincent H. J. van der elden, MD, Peter J.M. Valk, MD, PhD, Ugur Ozbek, MD, PhD, Lihui Wang, Gareth Gerrard, PhD, Helen E White, PhD, Thomas Schenk, MD, Thomas Ernst, MD, Rüdiger Hehlmann, MD, Giuseppe Saglio, MD, PhD, Andreas Hochhaus, MD, Nicholas C. P. Cross, PhD

Blood (2010) 116 (21): 893.

https://doi.org/10.1182/blood.V116.21.893.893

Published: 2010

Journal Articles

Harmonized Testing for BCR-ABL Kinase Domain Mutations In CML: Results of a Survey and First Control Round within 28 National Reference Laboratories In Europe

Blood (2010) 116 (21): 894.

https://doi.org/10.1182/blood.V116.21.894.894

Published: 2010

Journal Articles

BCR-ABL1 Oncogene Down-regulates the Expression of OCT1 in CML.

Alexandra Bazeos, David Marin, Gareth Gerrard, PhD, Richard Szydlo, Dragana Milojkovic, MD, Alistair Reid, Hugues de Lavallade, Jane F. Apperley, MBChB, FRCP, FRCPath, John M Goldman, DM, FCRP, FRCPath, Letizia Foroni, Jamshid Sorouri Khorashad, MD

Blood (2009) 114 (22): 3248.

https://doi.org/10.1182/blood.V114.22.3248.3248

Published: 2009

Journal Articles

Common Submicroscopic Genomic Imbalances Accompany the Ph Chromosome at Diagnosis in Chronic Myeloid Leukemia

Jamshid S Khorashad, MD, Valeria A De Melo, Heike Fiegler, PhD, Gareth Gerrard, PhD, Dan Brudzevsky, PhD, David Marin, MD, Jane F. Apperley, MBChB, FRCP, FRCPath, John M Goldman, DM, FRCP, FRCPath, Letizia Foroni, MD, PhD, FRCPath, Alistair G Reid, PhD

Blood (2008) 112 (11): 3113.

https://doi.org/10.1182/blood.V112.11.3113.3113

Published: 2008

Journal Articles

WT1 and PRAME Expression in CML: Quantitation by Real-Time PCR and Correlation with BCR-ABL Expression Levels

Gareth Gerrard, PhD, Caroline Cloke, BSc, Ian H Gabriel, Dr, Katayoun Rezvani, MD, PhD, Jane F. Apperley, MBChB, FRCP, FRCPath, Letizia Foroni, MD, PhD, FRCPath

Blood (2008) 112 (11): 4225.

https://doi.org/10.1182/blood.V112.11.4225.4225

Published: 2008

NARROW

Somatic Mutations in Epigenetic Modifiers Identified Using Next Generation Sequencing (NGS) in Diagnostic Samples of CML-CP Can Predict Poor Outcome on Imatinib Which Is Abrogated By Frontline 2G-TKI Therapy

Assessment of Molecular Response in CML Patients with Atypical BCR-ABL Tanscripts. Recommendations By the EUTOS Collaboration

NGS-Assisted DNA-Based Digital qPCR Facilitates Stratification Of CML Patients In Long-Term Molecular Remission Based On The Presence Of Detectable BCR-ABL1 DNA

Targeted High-Throughput Sequencing For The Detection Of Mutations Associated With Myeloproliferative Neoplasms

The Depth Of ‘Complete’ Molecular Response Predicts Molecular Relapse In Chronic Myeloid Leukaemia Patients On Tyrosine Kinase Inhibitor Therapy

Dose Interruption/Reduction Of Tyrosine Kinase Inhibitors In The First 3 Months Of Treatment of CML Is Associated With Inferior Early Molecular Responses and Predicts For An Increased Likelihood Of Discontinuation Of The 1st Line Agent

A Novel Splice Site Variant of hOCT-1 and Response to Imatinib.

Can Targeted Therapy for CML Still Learn From Transplant? Using Post-transplant RQ-PCR monitoring to Clarify the Importance of the Depth of Molecular Remission On the Risk of Subsequent Relapse.

Can the Combination of the Measurement of BCR-ABL1 Transcript Levels At 3 and 6 Months Improve the Prognostic Value of the 3 Month Measurement?

Is Major Molecular Response a Safe Haven Against Blast Crisis in Cml Patients Treated with Imatinib?

PTCH1 Expression At Diagnosis Reliably Predicts Treatment Failure in Imatinib-Treated Chronic Myeloid Leukaemia Patients

Target Enrichment and High-Throughput Sequencing of 80 Ribosomal Protein Genes to Identify Mutations Associated with Diamond-Blackfan Anaemia.

Prolonged Survival Following Imatinib Failure for CML Patients in CP May Require Multiple TKI Strategies for Responding Patients,

The Natural History of RTQ-PCR Levels After the Achievement of Complete Molecular Remission (CMR): Implications for ‘Stopping' Studies

Assessment of BCR-ABL1 Transcript Levels At 3 Months Is the Only Requirement for Predicting Outcome for Patients with Chronic Myeloid Leukemia Treated with Imatinib

Stability of Conversion Factors for BCR-ABL Monitoring -– Implications for the Frequency of Validation Rounds

Harmonized Testing for BCR-ABL Kinase Domain Mutations In CML: Results of a Survey and First Control Round within 28 National Reference Laboratories In Europe

BCR-ABL1 Oncogene Down-regulates the Expression of OCT1 in CML.

Common Submicroscopic Genomic Imbalances Accompany the Ph Chromosome at Diagnosis in Chronic Myeloid Leukemia

WT1 and PRAME Expression in CML: Quantitation by Real-Time PCR and Correlation with BCR-ABL Expression Levels

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only